<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311489</url>
  </required_header>
  <id_info>
    <org_study_id>ULA04</org_study_id>
    <secondary_id>2019-002268-28</secondary_id>
    <nct_id>NCT04311489</nct_id>
  </id_info>
  <brief_title>Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.</brief_title>
  <acronym>ULA04</acronym>
  <official_title>Single-center, Randomized, Double-blind, Placebo-controlled Clinical Trial for the Safety, Tolerability and Efficacy of Ularitide in Cirrhosis Patients With Refractory Ascites.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ADS AIPHIA Development Services AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial intends to investigate the safety, tolerability and efficacy of ularitide&#xD;
      on the renal response in patients with liver cirrhosis and refractory ascites for a maximum&#xD;
      exposure duration of 48 hours, through a randomized, placebo-controlled, double-blind,&#xD;
      single-center trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that ularitide infusion is more effective than placebo to&#xD;
      induce and maintain clinically meaningful natriuresis and diuresis in patients with liver&#xD;
      cirrhosis and refractory ascites.&#xD;
&#xD;
      Participants will be given ularitide or placebo intravenously while hospitalized at&#xD;
      Department of Hepatology and Gastroenterology at Aarhus University Hospital. During the&#xD;
      hospitalization blood and urine samples are frequently collected.&#xD;
&#xD;
      30 ng/kg/min is the starting dosage for all participants. Depending on effects and/or side&#xD;
      effects, ULA04 is designed to individualize treatment doses by up- and/or downtitration of&#xD;
      the infusion dose within a predefined dose range. Relevant safety precautions are&#xD;
      incorporated in the study design and treatment will be prematurely discontinued if a&#xD;
      pre-defined stopping criteria presents.&#xD;
&#xD;
      Patients will be followed up for the appearance of serious adverse events 30 days after the&#xD;
      treatment.&#xD;
&#xD;
      If a separate written consent is given by the participants, additional blood and urine&#xD;
      samples will be collected and stored in a biobank for future research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute and relative change in sodium excretion rate.</measure>
    <time_frame>After 24 hours and at termination of treatment (up to 48 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute and relative change in urine volume.</measure>
    <time_frame>After 24 hours and at termination of treatment (up to 48 hours)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of absolute body weight.</measure>
    <time_frame>At termination of treatment (up to 48 hours)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of responders in the ularitide group versus the placebo group, defined by:</measure>
    <time_frame>Throughout the treatment period. Latest measure at termination of treatment (up to 48 hours)</time_frame>
    <description>Urine volume increase of ≥100 % versus baseline, urine volume increase ≥50 % versus baseline, natriuresis increase by ≥100 % versus baseline and/or body weight reduction by ≥2 kg versus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in sodium excretion rate.</measure>
    <time_frame>After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in urine volume.</measure>
    <time_frame>After 2 hours and 4 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma cyclic guanosine monophosphate (cGMP) concentration.</measure>
    <time_frame>Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in waist circumference.</measure>
    <time_frame>After 24 hours and at termination of treatment (up to 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in serum creatinine.</measure>
    <time_frame>After 24 hours and at termination of treatment (up to 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in estimated glomerular filtration rate (eGFR).</measure>
    <time_frame>After 24 hours and at termination of treatment (up to 48 hours)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma and urine osmolalities.</measure>
    <time_frame>Throughout the treatment period. Latest measure at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in GFR-24h-Crea (Glomerular filtration rate based on 24-hour creatinine clearance).</measure>
    <time_frame>After 24 hours and 48 hours of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in hematocrit.</measure>
    <time_frame>After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma copeptin concentration.</measure>
    <time_frame>After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma renin concentration.</measure>
    <time_frame>After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma angiotensin concentration.</measure>
    <time_frame>After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and relative change in plasma aldosterone concentration.</measure>
    <time_frame>After 24 hours and 48 hours of treatment and at 6 hours post-treatment follow-up</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events/reactions.</measure>
    <time_frame>Throughout the treatment period and until 6 hours post-treatment follow-up</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of serious adverse events/reactions.</measure>
    <time_frame>Throughout the treatment period and until 30 days post-treatment follow-up</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of stopping criteria leading to a dose reduction.</measure>
    <time_frame>Throughout the treatment period (up to 48 hours)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of stopping criteria leading to early termination of treatment.</measure>
    <time_frame>Throughout the treatment period (up to 48 hours)</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <condition>Ascites Hepatic</condition>
  <arm_group>
    <arm_group_label>Ularitide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product. Continuous intravenous infusion with 30 ng/kg/min for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo. Continuous IV infusion for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ularitide</intervention_name>
    <description>Continuous intravenous infusion for 48 hours at a dose of 30 ng/kg/min. Depending on effect and/or side effects dose can be adjusted to 15 ng/kg/min or 45 ng/kg/min.</description>
    <arm_group_label>Ularitide</arm_group_label>
    <other_name>Urodilatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Continuous intravenous infusion for 48 hours at a bodyweight-adjusted infusion rate.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women &gt;18 years&#xD;
&#xD;
          -  Liver cirrhosis confirmed by fibroscan (&gt;20 kPa), or by imaging with signs of an&#xD;
             irregular liver surface with collaterals, or clinically by cirrhosis stigmata&#xD;
&#xD;
          -  Refractory ascites Definition: failure to respond to or intolerance to high dose&#xD;
             diuretics (spironolactone up to 400mg/day and furosemide up to 160mg/day) and early&#xD;
             ascites recurrence (reappearance of grade 2 or 3 ascites within 4 weeks of initial&#xD;
             mobilization or ≥2 paracentesis within last 3 months)&#xD;
&#xD;
          -  Urine sodium excretion &lt;60 mmol/24 hour&#xD;
&#xD;
          -  Serum creatinine &lt;150 µmol/L&#xD;
&#xD;
          -  Child-Turcotte-Pugh score of B or C (&lt;13)&#xD;
&#xD;
          -  Bilirubin &lt;150 µmol/L&#xD;
&#xD;
          -  Prothrombin time (PP) 0.20-0.60 (INR 1.3-2.5)&#xD;
&#xD;
          -  Systolic blood pressure ≥95 mmHg&#xD;
&#xD;
          -  Written informed consent to participate in the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Gastrointestinal bleeding within 2 weeks prior to inclusion&#xD;
&#xD;
          -  Proteinuria &gt;500 mg/day&#xD;
&#xD;
          -  Hemoglobin &lt;5.5 mmol/L&#xD;
&#xD;
          -  Spontaneous bacterial peritonitis within 2 weeks prior to inclusion&#xD;
&#xD;
          -  Loculated ascites&#xD;
&#xD;
          -  Hepatic encephalopathy grade 2-4 (West-Haven classification)&#xD;
&#xD;
          -  Obstructive uropathy&#xD;
&#xD;
          -  Primary kidney disease&#xD;
&#xD;
          -  Known diagnosis of congestive heart failure&#xD;
&#xD;
          -  Known diagnosis of acute-on-chronic liver failure&#xD;
&#xD;
          -  Known diagnosis of systemic inflammatory response syndrome&#xD;
&#xD;
          -  Acute infections by known diagnosis and/or antibiotic treatment&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Known allergy to the investigational drug or other natriuretic peptides&#xD;
&#xD;
          -  Treatment with dobutamine, levosimendan, milrinone, any phosphodiesterase inhibitor,&#xD;
             octreotide, midodrine, vasopressin, dopamine or other vasopressors within 2 weeks&#xD;
             prior to inclusion&#xD;
&#xD;
          -  Nephrotoxic drugs within 1 month prior to inclusion&#xD;
&#xD;
          -  Fertile women not using contraception, either an intrauterine device or hormonal&#xD;
             contraception&#xD;
&#xD;
          -  Positive pregnancy test in pre-menopausal women or in breast-feeding women&#xD;
&#xD;
          -  Participation in an interventional clinical drug trial within 1 month prior to&#xD;
             inclusion&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Patients who are employees or relatives of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Grønbæk, Prof,MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hepatology and Gastroenterology, Aarhus University Hospital,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henning Grønbæk, Prof,MD,PhD</last_name>
    <phone>+45 21 67 92 81</phone>
    <email>henngroe@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rasmus H Gantzel, MD</last_name>
    <phone>+45 40 87 92 22</phone>
    <email>ragant@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hepatology and Gastroenterology, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Central Denmark Region</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Grønbæk, Prof,MD,PhD</last_name>
      <phone>+45 21 67 92 81</phone>
      <email>henngroe@rm.dk</email>
    </contact>
    <contact_backup>
      <last_name>Rasmus H Gantzel, MD</last_name>
      <phone>+45 40 87 92 22</phone>
      <email>ragant@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Carstens J, Greisen J, Jensen KT, Vilstrup H, Pedersen EB. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites. J Am Soc Nephrol. 1998 Aug;9(8):1489-98.</citation>
    <PMID>9697672</PMID>
  </reference>
  <reference>
    <citation>Carstens J, Grønbaek H, Larsen HK, Pedersen EB, Vilstrup H. Effects of urodilatin on natriuresis in cirrhosis patients with sodium retention. BMC Gastroenterol. 2007 Jan 26;7:1.</citation>
    <PMID>17257428</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cirrhosis</keyword>
  <keyword>Ascites</keyword>
  <keyword>Refractory ascites</keyword>
  <keyword>Natriuresis</keyword>
  <keyword>Diuresis</keyword>
  <keyword>Urodilatin</keyword>
  <keyword>Ularitide</keyword>
  <keyword>natriuretic peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ularitide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

